The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor

Biomedicine and Pharmacotherapy

Volumn 68, Issue 6, 2014, Pages 721-727

  Setia, Shruti ^a   Nehru, Bimla ^a   Sanyal, Sankar Nath ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Angiogenesis; Colon cancer; PI3K pathway; Ulcerative colitis

Indexed keywords

BETA CATENIN; CELECOXIB; DEXTRAN SULFATE; DIMETHYLHYDRAZINE; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; WNT PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; COLITIS; COLON CARCINOMA; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE ASSOCIATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; ULCERATIVE COLITIS; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; COLONIC NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; CHEMOPREVENTION; COLITIS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; MICE; MICE, INBRED BALB C; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SULFONAMIDES;

EID: 84908082143     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.07.006     Document Type: Article

References (37)

1. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
2. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003, 18:1-5.
3. Boland C.R., Luciani M.G., Gasche C., Goel A. Infection, inflammation, and gastrointestinal cancer. Gut 2005, 54:1321-1331.
4. Janeway C.A., Travers P., Walport M., Shlomchik M.J. Immunobiology: The Immune System in Health and Disease 2001, Garland Science, New York. 5th ed.
5. Cho J.H., Kim H.O., Kim K.S., Yang D.H., Surh C.D., Sprent J. Unique features of naive CD8+ T cell activation by IL-2. J Immunol 2013, 191:5559-5573.
6. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
7. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9:667-676.
8. Broek R.V., Mohan S., Eytan D.F., Chen Z., Van Waes C. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, crosstalk, and therapies. Oral Dis 2013, 10.1111/odi.12206.
9. Saji M., Ringel M.D. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 2010, 321:20-28.
10. Ma J., Sawai H., Ochi N., Matsuo Y., Xu D., Yasuda A., et al. PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 2009, 331:161-171.
11. Hamada K., Sasaki T., Koni P.A., Natsui M., Kishimoto H., Sasaki J., et al. The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 2005, 19:2054-2065.
12. Pratheeshkumar P., Son Y.O., Budhraja A., Wang X., Ding S., Wang L., et al. Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS One 2012, 7:e52279.
13. Okumura N., Yoshida H., Kitagishi Y., Murakami M., Nishimura Y., Matsuda S. PI3K/AKT/PTEN signaling as a molecular target in leukemia angiogenesis. Adv Hematol 2012, 10.1155/2012/843085.
14. Jiang B.H., Liu L.Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009, 102:19-65.
15. Shafee N., Kaluz S., Ru N., Stanbridge E.J. PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett 2009, 282:109-115.
16. Pallero M.A., Elzie C.A., Chen J., Mosher D.F., Murphy-Ullrich J.E. Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis. FASEB J 2008, 22:3968-3979.
17. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual 1998, Cold Spring Harbor Laboratory Press, New York. 2nd ed.
18. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
19. Kanayama M., Takahara T., Yata Y., Xue F., Shinno E., Nonome K., et al. Hepatocyte growth factor promotes colonic epithelial regeneration via Akt signalling. Am J Physiol Gastrointest Liver Physiol 2007, 293:G230-G239.
20. LeBel C.P., Ischiopoulos H., Bondy S.C. Evaluation of the probe 2,7-dichlorofluorescein as indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992, 5:227-231.
21. Setia S., Sanyal S.N. Nuclear factor kappa B: a pro-inflammatory, transcription factor-mediated signalling pathway in lung carcinogenesis and its inhibition by non-steroidal anti-inflammatory drugs. J Environ Pathol Toxicol Oncol 2012, 31:27-37.
22. Stuehr D.J., Marletta M.A. Synthesis of nitrite and nitrate in murine macrophage cell lines. Cancer Res 1987, 47:5590-5594.
23. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
24. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007, 9:316-323.
25. Hemmings B.A., Restuccia D.F. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012, 4:a011189.
26. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012, 13:283-296.
27. Tao J., Xiong J., Li T., Yang Z., Li X., Li K., et al. Correlation between protein expression of PTEN in human pancreatic cancer and the proliferation, infiltration, metastasis and prognosis. J Huazhong Univ Sci Technol Med Sci 2006, 26:444-447.
28. Rak J., Yu J.L., Klement G., Kerbel R.S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Invest Dermatol Symp Proc 2000, 5:24-33.
29. Folkman J. What is the evidence that tumors are angiogenesis-dependent?. J Natl Canc Inst 1990, 82:4-6.
30. Jiang B.H., Zheng J.Z., Aoki M., Vogt P.K. Phosphatidylinositol 3- kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 2000, 97:1749-1753.
31. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000, 55:15-35.
32. Volpert O.V., Dameron K.M., Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997, 14:1495-1502.
33. Song Y., Dai F., Zhai D., Dong Y., Zhang J., Lu B., et al. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis 2012, 15:421-432.
34. Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., Vergari W.A., et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998, 90:587-596.
35. Amano K., Matsubara H., Iba O., Okigaki M., Fujiyama S., Imada T., et al. Enhancement of ischemia-induced angiogenesis by eNOS overexpression. Hypertension 2003, 41:156-162.
36. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.O., et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001, 98:2604-2609.
37. Setia S., Sanyal S.N. Downregulation of NF-κB and PCNA in the regulatory pathways of apoptosis by cyclooxygenase-2 inhibitors in experimental lung cancer. Mol Cell Biochem 2012, 369:75-86.